Reproductive health startup raises $65M for infertility drugs
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
ReproNovo, a biotechnology company specializing in reproductive medicine, has raised $65 million to advance two drugs it thinks could help address fertility issues in men and women.
The Switzerland-based firm plans to use the new funds to run Phase 2 clinical trials of the drugs. The first, called leflutrozole, is designed to treat infertility in men with low testosterone, while the second, nolasiban, will be studied in women with a gynecological disorder called adenomyosis and as an adjunctive therapy alongside assisted reproductive technologies.
'We are here to fill the critical gaps for patients in reproductive medicine and women's health,' Jean Maire Duvall, CEO and co-founder of ReproNovo, told BioPharma Dive.
Founded in 2021, ReproNovo gained rights to the candidates through licensing deals with Mereo BioPharma and ObsEva, respectively.
Leflutrozole is a small molecule that works by blocking an enzyme called aromatase. This effect, ReproNovo says, could help stabilize levels of testosterone and address male infertility. Some research has raised concerns about declines in male reproductive health, as fertility rates among women in the U.S. have also fallen.
Although infertility impacts both men and women, the pressure and responsibility for solving the issue often falls on the woman. 'We'd like to offer an alternative where the male could be treated directly,' said Duvall.
Nolasiban blocks oxytocin receptors, which ReproNovo sees as potentially helpful in managing adenomyosis, a condition where endometrial tissue grows in the uterine walls. Adenomyosis can cause similar symptoms as endometriosis, such as pelvic pain and heavy menstrual bleeding. The condition often occurs in women between the ages of 35 to 50. There are no drugs specifically approved to treat it.
ReproNovo is also studying whether nolasiban can improve embryo implantation by reducing uterine contractility and enhancing blood flow amid embryo transfer during in vitro fertilization. While other treatments are available and in development to increase the chances of IVF success, none are approved to support embryo implantation specifically, the company said.
The Series A funding round was led by Jeito Capital and co-led by AXA IM Alts and ReproNovo's founding investor M Ventures, the venture arm of Merck KGaA. Ysios Capital and Alsa Ventures also participated.
Recommended Reading
Women's health faces growing headwinds, despite jump in venture investment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Macron says Europe must become 'space power' again
President Emmanuel Macron said Friday that Europe must again become a global space power, warning that France risked being squeezed out of the global low-orbit satellite constellation market. Macron spoke at the Paris Air Show in Le Bourget outside the French capital a day after France more than doubled its stake in satellite operator Eutelsat, the EU rival to Elon Musk's Starlink. Macron called for more investment as the European space industry struggles to remain competitive in the face of US and Chinese rivals. "SpaceX has disrupted the market, Amazon is also getting involved. China is not far behind, and I think we all need to be very clear-headed," Macron said. Europe must become "a space power once again, with France at its heart", he said. He warned that Europeans were "on the verge of being completely" squeezed out of the low Earth orbit (LEO) satellite constellation market. Orbiting just a few hundred kilometres above the Earth, low Earth orbit satellite networks can play a crucial role in various fields including telecommunications, emergency response, space exploration, and defence. Growing geopolitical tensions have forced countries to focus on the independence of their satellite infrastructure. Macron said France and its partners should not be reliant on non-European constellations in low orbit, calling it "madness". He called non-European players to team up with France. "This must be the solution for our major strategic partners in the Gulf, India, Canada and Brazil," he said. "We really need to succeed in increasing our collective investment effort," Macron added, noting the importance of private investors and public-private collaboration. He also said France planned to organise a space summit in early 2026 to "mobilise our public and private partners across the globe." As part of the overall deal with other investors worth 1.35 billion euros ($1.5 billion), the French state is set to become Eutelsat's largest shareholder. The European satellite operator is vying to be seen as an alternative to Starlink, as companies in Europe and elsewhere look askance at Musk's manoeuvrings and seek to secure sovereign solutions. Boasting more than 600 satellites since merging with British firm OneWeb in 2023, Eutelsat is the world's second-largest operator of low Earth orbit satellites, behind Starlink. fff-tq-as/ekf/js
Bloomberg
5 hours ago
- Bloomberg
UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn
Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.
Yahoo
6 hours ago
- Yahoo
PharmaSens and SiBionics to develop wearable insulin patch pump
Swiss company PharmaSens and SiBionics have entered a development partnership for niia signature, an all-in-one wearable that integrates the delivery of insulin with continuous glucose monitoring (CGM) into a compact pump. Through this device, the parties anticipate simplifying the management of diabetes for individuals who utilise insulin, aiming to minimise the daily therapy load. The wearable will leverage PharmaSens' patented platform technologies along with the biosensor capabilities of SiBionics. Both companies will offer their engineering and development know-how to bring this patch pump to the market. PharmaSens CEO Marcel Both said: 'This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system. 'SiBionics' proven expertise in sensor technology is a perfect complement to our platform.' PharmaSens is currently developing a portfolio of three insulin patch pumps, including niia signature, designed to cater to a broad range of user needs. The range begins with the niia essential, a basal-bolus insulin pump that prioritises ease of use by minimising complexity. The niia advanced provides additional options and can be controlled through a smartphone, also allowing connection to an external CGM. PharmaSens highlights that its devices consist of one reusable part, comprising the pump and CGM electronics with a two-year lifespan, and one disposable part, which includes a 3ml insulin reservoir to extend wear time and reduce insulin waste. The company is focused on simplifying diabetes management and expanding access to insulin pump therapy. Founded in 2015, CGM technology provider SiBionics brings to the partnership its core expertise in medical device research and development, with offices in China and the US. Last year, PharmaSens submitted an application to the US Food and Drug Administration (FDA) for approval of its niia essential insulin patch pump system. "PharmaSens and SiBionics to develop wearable insulin patch pump" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
